Human FGFR3 ELISA Kit

Product details

Human FGFR3 ELISA Kit (ab214027) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of FGFR3 protein in cell culture extracts and tissue extracts. It uses our proprietary SimpleStep ELISA® technology. Quantitate Human FGFR3 with 61 pg/ml sensitivity.

SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:

- Single-wash protocol reduces assay time to 90 minutes or less
- High sensitivity, specificity and reproducibility from superior antibodies
- Fully validated in biological samples
- 96-wells plate breakable into 12 x 8 wells strips

A 384-well SimpleStep ELISA® microplate (ab203359) is available to use as an alternative to the 96-well microplate provided with SimpleStep ELISA® kits.

FGFR3 is a tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. FGFR3 plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. FGFR3 regulates both osteogenesis and postnatal bone mineralization by osteoblasts. FGFR3 promotes apoptosis in chondrocytes, but can also promote cancer cell proliferation. FGFR3 is required for normal development of the inner ear. FGFR3 interacts in vitro with FGF1, FGF2, FGF4, FGF6; FGF8, FGF9, FGF10, FGF17, FGF18, FGF19, FGF20 and FGF23. FGFR3 interacts with KLB. The affinity for fibroblast growth factors (FGFs) is increased by heparan sulfate glycosaminoglycans that function as co-receptors. Likewise, KLB increases the affinity for FGF19 and FGF21. FGFR3 interacts with PIK3R1, PLCG1, SOCS1 and SOCS3. FGFR3 isoform 3 forms disulfide-linked dimers. Ligand binding to FGFR3 leads to FGFR3 dimerization and to the activation of several signalling cascades. FGFR3 phosphorylates PLCG1, CBL and FRS2. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR3 plays a role in the regulation of vitamin D metabolism. Mutations that lead to constitutive kinase activation or impair normal FGFR3 maturation, internalization and degradation lead to aberrant signaling. Over-expressed or constitutively activated FGFR3 promotes activation of PTPN11/SHP2, STAT1, STAT5A and STAT5B. Secreted isoform 3 of FGFR3 retains its capacity to bind FGF1 and FGF2 and hence may interfere with FGF signalling.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.